Category Archives: Healthcare

Healthcare

Botox Training with the IAPAM Helps Physicians Grow Their Healthcare Businesses

Leave a comment

As the demand for minimally-invasive treatments continues to rise, specifically the demand for Botox, dermal fillers and other cosmetic injectables, physicians who are expertly trained through multi-day botox training programs like the IAPAM’s Aesthetic Medicine Symposium, can capture this growing market and greatly benefit their practice’s bottom line.

Las Vegas, NV, Friday – July 08, 2011 — As reported by the IAPAM and other aesthetic medicine associations, there were 11.6 million cosmetic minimally-invasive procedures performed in 2010, and 5.4 million of these were botox injections and other neurotoxin treatments.

The IAPAM ( http://www.iapam.com ) confirms this trend, noting that each of their Aesthetic Medicine Symposiums ( http://www.aestheticmedicinesymposium.com ) and its Botox and Dermal Filler Bootcamps and its Advanced Filler Training programs has sold out in the first half of 2011. Furthermore, while Botox training is still very popular, more and more physicians are also appreciating that the key to a successful and profitable aesthetic practice is not just offering Botox treatments, but also other skin rejuvenation procedures including: chemical peels, microdermabrasion, Laser/IPL skin rejuvenation, and physician-directed skin care.

In order to profitably add aesthetic medicine to a practice, physicians need to incorporate these key fundamentals, as taught at the IAPAM’s Aesthetic Medicine Symposium:

– Understanding the latest trends in aesthetic medicine and how to use them to one’s advantage;
– How to develop a successful business plan including steps on how to integrate medical aesthetics procedures into a practice or build a patient base;
– How to perform aesthetic patient consultations;
– How to add the most profitable cosmetic injectable procedures, including: Botox ®, and dermal fillers (i.e. Juvederm ®, Restylane ®, and Perlane ®), chemical peels, and physician directed skin care;
– Extensive, physician-led, hands-on training in Botulinum Toxin Type A (i.e. Botox®), IPL / laser technology, and medical microdermabrasion; and
– How to maximize profits by offering the most profitable aesthetic medicine procedures like physician strength chemical peels, tailored to meet a clinic’s specific patient profiles.

The IAPAM’s Aesthetic Medicine Symposium program is unique in addressing all of these issues.

Physicians learn best practices from the IAPAM’s faculty physicians and experienced instructors, and botox training a key component of the IAPAM’s Aesthetic Medicine Symposium, which also offers expert instruction in: Dermal Fillers, Microdermbarsion, Chemical Peels, and Lasers and Light Treatments & Hair Removal. this does not read right to me, but not sure how to reword it.

Leading the training is a team of renowned cosmetic dermatologists who will cover aesthetic patient consultations, facial anatomy & musculature, Botox ® and Dysport ® product preparation, pain management, procedural protocols, post treatment issues and continuing patient support.

IAPAM’s Aesthetic Medicine Symposium is the only multi-day training program that also offers one year of unlimited practice support to all registrants. Indeed, physicians who have attended the IAPAM’s Symposium, raved that, “the support you get from IAPAM afterwards definitely makes the course different than the others.” Also, the conference materials provided allow each attendee and their staff to review the key content of the aesthetic medicine conference. These materials include: the complete Building a Successful Cosmetic Medical Business training program (16 training DVD’s, including: Mastering the Consultation Process, Guide to Selling Photofacials, Marketing Your Cosmetic Practice, Sell Injectables and Explode Your Business, etc. as well as leader guide and 5 staff workbooks.)

For additional information and to register for an upcoming Aesthetic Medicine Symposium in Scottsdale, Arizona, please contact the Lynn at the IAPAM at 1-800-219-5108 ext. 704, or visit http://www.aestheticmedicinesymposium.com.

Botox is a trademark of Allergan, Inc.

About the International Association for Physicians in Aesthetic Medicine:
The International Association for Physicians in Aesthetic Medicine is a voluntary global association of physicians and supporters, which sets standards for the aesthetic medical profession worldwide. The goal of the association is to offer education, ethical standards, credentialing, and member benefits to members around the globe. IAPAM membership is open to all licensed medical doctors (MDs), doctors of osteopathic medicine (DOs), physicians assistants (PAs) and nurse practitioners (NPs). The IAPAM offers aesthetic medicine and hCG medical weight management programs, including: Botox training, medical aesthetic training, laser training, physician hCG training, and aesthetic practice business training. Additional information about the association can be accessed through the IAPAM’s website ( http://www.iapam.com ) or by contacting:

Websites:
http://www.AestheticMedicineSymposium.com
http://www.iapam.com/advancedfillertraining.html
http://www.aestheticmedicinesymposium.com/botoxtraining
http://www.iapam.com/botoxtraining.html
http://www.iapam.com/category/testimonials

Twitter: http://www.twitter.com/IAPAM
Facebook: http://www.facebook.com/IAPAM

Press & Media Contact:
Jeff Russell, Executive-Director
International Association for Physicians in Aesthetic Medicine (IAPAM)
848 N. Rainbow Blvd., #713
Las Vegas, NV 89107
1-800-219-5108 x704
info@theiapam.com
http://www.iapam.com

Healthcare

IAPAM’s Botox Training Helps Physicians Boost Profits

Leave a comment

As the demand for minimally-invasive treatments continues to rise, specifically the demand for Botox, dermal fillers and other cosmetic injectables, physicians who are expertly trained through multi-day botox training programs like the IAPAM’s Aesthetic Medicine Symposium, can capture this growing market and greatly benefit their practice’s bottom line.

Las Vegas, NV, Friday – July 08, 2011 — As reported by the IAPAM and other aesthetic medicine associations, there were 11.6 million cosmetic minimally-invasive procedures performed in 2010, and 5.4 million of these were botox injections and other neurotoxin treatments.

The IAPAM ( http://www.iapam.com ) confirms this trend, noting that each of their Aesthetic Medicine Symposiums ( http://www.aestheticmedicinesymposium.com ) and its Botox and Dermal Filler Bootcamps and its Advanced Filler Training programs has sold out in the first half of 2011. Furthermore, while Botox training is still very popular, more and more physicians are also appreciating that the key to a successful and profitable aesthetic practice is not just offering Botox treatments, but also other skin rejuvenation procedures including: chemical peels, microdermabrasion, Laser/IPL skin rejuvenation, and physician-directed skin care.

In order to profitably add aesthetic medicine to a practice, physicians need to incorporate these key fundamentals, as taught at the IAPAM’s Aesthetic Medicine Symposium:

– Understanding the latest trends in aesthetic medicine and how to use them to one’s advantage;
– How to develop a successful business plan including steps on how to integrate medical aesthetics procedures into a practice or build a patient base;
– How to perform aesthetic patient consultations;
– How to add the most profitable cosmetic injectable procedures, including: Botox ®, and dermal fillers (i.e. Juvederm ®, Restylane ®, and Perlane ®), chemical peels, and physician directed skin care;
– Extensive, physician-led, hands-on training in Botulinum Toxin Type A (i.e. Botox®), IPL / laser technology, and medical microdermabrasion; and
– How to maximize profits by offering the most profitable aesthetic medicine procedures like physician strength chemical peels, tailored to meet a clinic’s specific patient profiles.

The IAPAM’s Aesthetic Medicine Symposium program is unique in addressing all of these issues.

Physicians learn best practices from the IAPAM’s faculty physicians and experienced instructors, and botox training a key component of the IAPAM’s Aesthetic Medicine Symposium, which also offers expert instruction in: Dermal Fillers, Microdermbarsion, Chemical Peels, and Lasers and Light Treatments & Hair Removal. this does not read right to me, but not sure how to reword it.

Leading the training is a team of renowned cosmetic dermatologists who will cover aesthetic patient consultations, facial anatomy & musculature, Botox ® and Dysport ® product preparation, pain management, procedural protocols, post treatment issues and continuing patient support.

IAPAM’s Aesthetic Medicine Symposium is the only multi-day training program that also offers one year of unlimited practice support to all registrants. Indeed, physicians who have attended the IAPAM’s Symposium, raved that, “the support you get from IAPAM afterwards definitely makes the course different than the others.” Also, the conference materials provided allow each attendee and their staff to review the key content of the aesthetic medicine conference. These materials include: the complete Building a Successful Cosmetic Medical Business training program (16 training DVD’s, including: Mastering the Consultation Process, Guide to Selling Photofacials, Marketing Your Cosmetic Practice, Sell Injectables and Explode Your Business, etc. as well as leader guide and 5 staff workbooks.)

For additional information and to register for an upcoming Aesthetic Medicine Symposium in Scottsdale, Arizona, please contact the Lynn at the IAPAM at 1-800-219-5108 ext. 704, or visit http://www.aestheticmedicinesymposium.com.

Botox is a trademark of Allergan, Inc.

About the International Association for Physicians in Aesthetic Medicine:
The International Association for Physicians in Aesthetic Medicine is a voluntary global association of physicians and supporters, which sets standards for the aesthetic medical profession worldwide. The goal of the association is to offer education, ethical standards, credentialing, and member benefits to members around the globe. IAPAM membership is open to all licensed medical doctors (MDs), doctors of osteopathic medicine (DOs), physicians assistants (PAs) and nurse practitioners (NPs). The IAPAM offers aesthetic medicine and hCG medical weight management programs, including: Botox training, medical aesthetic training, laser training, physician hCG training, and aesthetic practice business training. Additional information about the association can be accessed through the IAPAM’s website ( http://www.iapam.com ) or by contacting:

Websites:
http://www.AestheticMedicineSymposium.com
http://www.iapam.com/advancedfillertraining.html
http://www.aestheticmedicinesymposium.com/botoxtraining
http://www.iapam.com/botoxtraining.html
http://www.iapam.com/category/testimonials

Twitter: http://www.twitter.com/IAPAM
Facebook: http://www.facebook.com/IAPAM

Press & Media Contact:
Jeff Russell,
Executive-Director
International Association for Physicians in Aesthetic Medicine (IAPAM)
848 N. Rainbow Blvd., #713
Las Vegas, NV 89107
1-800-219-5108 x704
info@theiapam.com
http://www.iapam.com

Healthcare, Internet & Online, Pharmaceuticals

Recently Launched Pharmacy Xpressdelivery.Com Offers Fair Deals On Popular Drugs

Leave a comment

Jun 27 2011 /RTPR/ – New online pharmacy xpressdelivery.com has been launched, offering its services to international customers. This is the first online drugstore to offer cheap generic Viagra online and other impotence medications at a fair price.

Xpressdelivery.com was launched with an understanding of the market lacking a pharmacy that would be truly committed to providing high level of service without charging too much money. This pharmacy was started as a place where it would be possible to buy viagra online, as well as purchase some other highly demanded medications that can be very expensive to buy without a prescription. Because of the company’s close cooperation with the largest manufacturer of cheap generic drugs (generic Viagra being one of them), xpressdelivery.com can offer affordable prices and more options for the customer to save money and leave satisfied. The pharmacy is ready to offer convenient shopping options to its customers, and new ones are introduced every day.

Xpressdelivery.com is planning to become truly international and popular with customers looking to save their money without the quality of their generic Viagra affected. Presently, it’s looking into the opportunity to cooperate with another large manufacturer, that way being able to offer a wider choice of medications at even more attractive prices. Due to years of experience its members of staff have, as well as constant attention to perfecting the services offered to new and regular customers, this pharmacy has already found its niche in the market and will keep working on bringing more advantages to people interested in saving money while shopping for their drugs online.

Xpressdelivery.com is a recently launched online pharmacy that sells most popular and very efficient generic medications. Xpressdelivery.com is a fully licensed pharmacy committed to providing all the safety guarantees to its customers. Independent international institutions carefully monitor the work of this online drugstore, which guarantees every visitor an increased level of security and confidentiality.

Contact Details: 848 N. Rainbow Blvd. #1707 Las Vegas, NV 89107
413-241-7404, 800-400-8079
Fax Number:
US:1-413-638-0491

###

 

Biotech, Chemicals, Healthcare, Science

Enabling microRNA Discoveries – 250th Peer-Reviewed Publication Made Possible By µparaflo Custom Microarray Technology

Leave a comment

Jun 09 2011 /RTPR/ – LC Sciences, a life sciences company leading the development of innovative microRNA (miRNA) analysis and discovery technologies, announced today the publication of over 250 peer-reviewed studies using the company’s microarray service for analyzing miRNA expression profiles. These studies, by leading researchers in the field, represent significant steps toward realizing these small regulatory RNA’s potential as biomarkers and therapeutic targets.

MiRNAs have proven to be an extremely important part of the gene expression regulation mechanism of a wide variety of cellular processes. This is evident in the amount of relevant findings by LC Sciences’ customers being translated into published reports and the diverse range of study areas that these publications encompass: cancer research, neuroscience, cardiovascular research, reproductive biology, plant science, microbiology, immunology and stem cell research. LC Sciences’ miRNA profiling service, powered by its µParaflo® custom microarray technology, provides quick, reliable, fully analyzed datasets enabling researchers to immediately move forward with groundbreaking research.

The miRNA field is still nascent, and it is advancing rapidly. The race to discovery has produced a continuous stream of new miRNA sequences as well as routine revisions of inaccurate or incomplete sequences. This fluidity has caused many microarrays with static content to fall away and has fueled reports of the wholesale replacement of microarrays by new methods such as RNA-Seq. But the nimble, customizable format of the µParaflo® array has given it staying power, not only by enabling it to keep current with all known miRNAs, but also by making use of data generated by RNA-Seq. These custom arrays have benefited from RNA-sequencing generating novel content that other arrays are unable to capture and take advantage of.

The 250th study, entitled “Wolbachia uses host microRNAs to manipulate host gene expression and facilitate colonization of the dengue vector Aedes aegypti.” appeared in the May 31st issue of PNAS and was one of a group of articles published recently by LC Sciences’ customers describing microarray expression analysis of miRNAs recently discovered through RNA Sequencing.

Researchers at the University of Queensland, Australia studied the underlying mechanisms of host manipulation by a widespread endosymbiont. Using microarrays, they show that the miRNA profile of the mosquito, Aedes aegypti, is significantly altered by a life-shortening strain of W. pipientis bacteria. This is extremely important work as introduction of Wolbachia into mosquitoes has been proposed as a method for malaria control. They found that a host miRNA (aae-miR-2940) is induced after W. pipientis infection in both mosquitoes and cell lines.

This study illustrates the versatility of µParaflo® from a couple of perspectives. First, mosquito, an important though non-model species was the target of interest here and mosquito arrays, as well as arrays from any of the 153 species listed in the miRBase public sequence database, are readily available from LC Sciences. Second, custom content (novel miRNA sequences from an earlier sequencing study on the same species) was quickly integrated into the content of the insect array providing an even richer expression dataset. Though all the previously described, known insect miRNAs were also present on the arrays, several custom sequences were significantly differentially expressed in infected mosquitoes and a custom sequence turned out to be one that became a focus of the investigation. Dr. Sassan Asgari, lead researcher for the study, commented that microarrays “…provided an affordable approach to the study of differential expression of small RNAs and miRNAs in particular.”

“We are very excited about the announcement of the 250th peer-viewed publication by one of our microarray customers,” says Chris Hebel, VP of Business Development at LC Sciences. “We were the first to provide a microarray expression profiling service for miRNA back in 2005 and proud to be still going strong in the face of rapidly advancing technologies, while many other less adaptable arrays, have fallen away. Despite the apparent advantages of new technologies such as RNA-Seq, microarrays have been the gene expression workhorse for many years and continue to be a robust, affordable solution. High-throughput RNA sequencing is still significantly more expensive and it won’t be until there is sufficient multiplexing of samples when we finally do reach a cost approaching that of microarrays. Of course more samples means less coverage per sample, and I think we’re still trying to figure out just how much coverage is required for robust expression data from deep sequencing and therefore what level of multiplexing can ultimately be reached. Meanwhile, RNA-Seq has become an amazing tool for discovery of novel miRNAs and continues to provide new content for our custom microarrays.”

About µParaflo® Technology – The µParaflo® technology is a microfluidic platform for in situ parallel synthesis of biomolecular chips and miniaturization of bioassays including hybridization, binding and enzymatic reactions. This unique platform technology is based on pico-liter microfluidic reaction devices and a digital light controlled synthesis method that employs conventional oligonucleotide or peptide synthesis chemistry; a completely programmable process. The seamless integration of these multidisciplinary technologies enables a significant advance in
parallelization, miniaturization, customization, and automation.

About LC Sciences – LC Sciences offers discovery, profiling and validation services for microRNA and other small RNAs. Services include deep sequencing for discovery applications, microarrays for differential expression profiling and validation/confirmation of newly discovered microRNAs, and qRT-PCR for quantitation of microRNA expression levels. These comprehensive services are designed to be one-stop and produce the results needed to quickly advance your biological and biomedical research. Combining the latest deep sequencing technology with ourµParaflo® on chip synthesis technology offers unprecedented flexibility and customization capability.

More information about LC Sciences is available at www.lcsciences.com.

Hussain M, Frentiu FD, Moreira LA, O’Neill SL, Asgari S. (2011) Wolbachia uses host microRNAs to manipulate host gene expression and facilitate colonization of the dengue vector Aedes aegypti. Proc Natl Acad Sci USA 108(22), 9250-55.

Contact Details: Chris Hebel
LC Sciences LLC
2575 West Bellfort St, Ste 270
Houston, TX 77054
713-664-7087
FAX 713-664-8181
chebel@lcsciences.com
www.lcsciences.com
chebel@lcsciences.com

 

Biotech, Healthcare, Science, Society

This Sunday will mark the 30th anniversary of the first reports of AIDS in the United States

Leave a comment

Jun 06 2011 /RTPR/ – This Sunday will mark the 30th anniversary of the first reports of AIDS in the United States. There is still a long road ahead toward eradicating HIV, but a “dream team for HIV reservoirs cure” has been created since 2003 with this objective.

While the HIV pandemic is still growing, with more than 7,100 daily new cases of infection, there is evidence that antiretroviral therapy costs could treble over the next 20 years.

Today there are more than 30 drugs approved to treat HIV, and while they cannot cure it, they can keep the virus suppressed to undetectable levels in blood. But HIV persists dormant in some “reservoir” and each time antiretroviral therapy is stopped, the infection rekindles. Lifelong therapy is therefore mandatory but brings problems of compliance, resistance, toxicity and cost.

These reservoirs were first described in 1997 and 5 years later Alain Lafeuillade, a French Doctor involved in HIV research, considered that it would be the challenge of the 21st Century. He consequently founded a working group uniting researchers from all over the world that first met in December 2003. This first “HIV Reservoirs, Persistence and Eradication Strategies Workshop” welcomed around 130 scientists actively involved in the field. “At that time we were seen as utopists, Doctor Lafeuillade said, and quite ignored by funding agencies and pharmaceutical companies”.

But minds greatly changed in the following years and in 2009, when the “dream team” met for the 4th time, the workshop was officially supported by the NIH (National Institutes of Health) and the ANRS (French Agency for AIDS Research). In between 2 workshops, the group of scientists are in touch via a specialized website portal they also have created.

“At the end of this year we will reconvene, Doctor Lafeuillade added, and be more than 200 scientists working on HIV cure”. The program of this 5th workshop goes from in vitro models of HIV persistence to HIV eradication clinical trials. “Participants will be able to define a clear road map for HIV cure research with a precise agenda”, Doctor Lafeuillade emphasized.

About the “HIV Reservoirs, Persistence and Eradication Strategies Workshop” Committees: founding fathers are Alain Lafeuillade (France), Mario Stevenson (USA), Robert Gallo (USA), Jose Gatell (Spain) and Christine Rouzioux (France). The scientific board contains David Margolis (USA), Jose Alcami (Spain), Tae-Wook Chun (USA), Mark Wainberg (Canada), Nicolas Chomont (USA), Monsef Benkirane (France), Françoise Barre-Sinoussi (France), Marie-Lise Gougeon (France)… Web site:http://www.informedhorizons.com/persistence2011/index.html

Contact: Alain Lafeuillade, informed Horizons, LLC
1860 Montreal Road, Suite 2, Tucker GA 30084 USA
Tel: +1 770 573 3020 | Fax: +1 866 534 6438
E-mail: kmorris@informedhorizons.com
Web site: http://www.informedhorizons.com/persistence2011/index.html

Healthcare

AllPetNaturals Now Largest Fan Page on Facebook For Natural Pet Health Care

Leave a comment

AllPetNaturals announced today that it has surpassed 5,000 people on its Facebook fan page, making it the largest online community solely dedicated to natural pet medicine and holistic pet health.

Ferndale, WA, May 18, 2011 — AllPetNaturals ( http://www.allpetnaturals.com ) announced today that it has surpassed 5,000 people on its Facebook fan page, making it the largest online community solely dedicated to natural pet medicine and holistic pet health.

“We are delighted so many people interact with our fan page every day,” says William Greenbaum, who established the company in 2009. “We’re proud to be able to provide a helpful forum where pet lovers can share ideas about natural health for their dogs, cats and horses and get tips about different healing modalities such as homeopathy, herbal remedies, aromatherapy, acupuncture, and energy medicine.”

The most active fans of AllPetNaturals are located in the United States, Brazil, and the Philippines. Seventy percent of fans are women between the ages 35 to 54.

Facebook is the most popular destination on the Internet with over 500 million users. Just after Facebook went live in 2005, it introduced a public profile, known as a “Fan Page” enabling businesses or individuals to directly interact with their customers and friends.

AllPetNaturals utilizes Facebook as a valuable communications and branding tool to reach people with the latest information about natural health and effective natural remedies for numerous pet health conditions.

AllPetNaturals.com is the premier online web store for natural health products for pets including herbal remedies, homeopathic remedies, essential oils, diet supplements, vitamins, pet treats and unique eco friendly toys, furniture and accessories.

For more information about AllPetNaturals, contact William Greenbaum. info@allpetnaturals.com.

USA Head Office: 1465 Slater Road, Ferndale, WA 98248
Toll Free 1.877.232.7387
http://www.allpetnaturals.com

Press & Media Contact:
William Greenbaum, President
All Pet Naturals
1465 Slater Road
Ferndale, WA 98248
778-238-7410
bill@allpetnaturals.com
http://www.allpetnaturals.com

Healthcare

Elder Pharma Posts Higher Net Revenue of Rs. 302.71 Cr for Q4 Ended March 2010-11 – Up By 60%

Leave a comment

* PAT grows by 11% in FY2011
* Shelcal K and Shelcal HD gaining traction
* Completes NCD program of Rs. 118.80 Cr and Rs. 73.00 Cr in two separate Tranches
* Launches I-Vit Plus; Launches Somazina Plus

Mumbai, India, May 11, 2011 — Elder Pharmaceuticals Ltd (NSE- ELDERPHARM) ( http://www.elderindia.com ) an integrated pharmaceuticals company headquartered in Mumbai has posted robust results for the fourth quarter ended March 2011 (Q4 FY2011). As per the consolidated unaudited provisional results taken on record on May 10th, 2011, the income from operations has gone up to Rs 3,027.14 Crore for Q4-FY2011 as compared to Rs. 1,896.94 Crore during the corresponding quarter in the previous year. The consolidated operating profit (PBIDT) too has gone up to Rs. 523.52 Crore for Q4 FY2011 reflecting a growth of 40% over the previous corresponding quarter’s figure of Rs. 374.86 Crore. The consolidated Net Profit for Q4 FY2011 stood at Rs. 172.76 Crore. The consolidated EPS on a non – annualized basis stood at Rs. 8.41 for Q4 FY2011 and at Rs. 30.03 for FY2011.

For the twelve months ended March 2011, the unaudited consolidated sales turnover is Rs. 9,592.03 Cr (previous 12 months- Rs. 7,208.98 Cr – audited) up by 33% and the unaudited Net Profit is Rs. 616.76 Cr (previous 12 months – Rs 553.92 Cr – audited) up by 11%.

During the quarter under review, the Company completed its NCD raising program to augment medium to long term resources including regular capital expenditure. First tranche of Rs. 118.80 Crore and Second Tranche of Rs. 73.00 Crore were completed on 23rd Dec’2010 and 31st March 2011 respectively.

The Company launched I-Vit Plus and Somazina Plus during the quarter under review.

* I-Vit Plus is a blend of micro-nutrients helpful in providing adequate mineral/vitamin and essential nutrient supplementation for correcting suboptimal vitamin/mineral intake.

* Somazina Plus is a unique combination of Citicholine with Piracetam that improves brain function and stimulates the central nervous system thus offering neuroprotection and enhancing cognition.

Elder Pharmaceuticals has presence in niche therapeutic segments like Women’s healthcare, Wound care, Nutraceuticals /vitamin Supplements, Cardiology, Diabetes, Dermatology, Antibiotics and neurology. It is the market leader in calcium supplements (Shelcal), wound healing and injectable B12 vitamin. The company has a judicious mix of drug formulations, and active pharma ingredients (APIs). It has 6 manufacturing plants in India located in Maharashtra, Uttarakhand & Himachal Pradesh. The company has a state-of-the-art Research & Development Centre at Navi Mumbai which is recognized by the Department of Scientific & Industrial Research, Ministry of Science & Technology. ( http://www.elderindia.com ).

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com

Biotech, Business, Financial, Healthcare, Religion, Science, Society

Advanced Cell Technology has pioneered a solution to the ethical, moral & legal debate raging in regards to protection of a human embryo

Leave a comment

May 10, 2011 /RTPR/– Advanced Cell Technology with laboratory facilities in Marlborough Massachusetts has pioneered a solution to the ethical, moral & legal debate raging in regards to protection of a human embryo. ACT has developed the “single-blastomere” technique. Patent Number 7,893,315 a non-destructive alternative for deriving human embryonic stem cell (hESC) lines.

This achievement in Regenerative medicine is a ground breaking feat for both Catholic and U.S. law.

• The 1995 encyclical The Gospel of Life, of which Pope John Paul II wrote: “Human embryos obtained in vitro are human beings and are subjects with rights; their dignity and right to life must be respected from the first moment of their existence. It is immoral to produce human embryos destined to be exploited as disposable ‘biological material'” (1,5 )
• The Dickey Amendment (also known as the Dickey-Wicker Amendment) is the name of an appropriation bill rider attached to a bill passed by United States Congress in 1995, and signed by former President Bill Clinton, which prohibits the Department of Health and Human Services (HHS) from using appropriated funds for the creation of human embryos for research purposes or for research in which human embryos are destroyed.

The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential. The stem cells generated using this approach are healthy, completely normal, and differentiate into all the cell types of the human The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world. ACT’s technique of protecting the human embryo from harm can be expounded to the smallest blood transfusion in the world. As does a human being give millions of blood cells in a pint of blood so does ACT’s “single blastomere” process take but “one cell” from a 2 day old embryo. As the blood removed from a human donor “regenerate” the removed pint of blood so does the human embryo “regenerate” the one cell. Both of these procedures leave the human body & two day old embryo healthy. Both procedures are similar in that they both provide life saving material to those whom need them most to due to disease and other aliments of a medical nature.

Advanced Cell Technology has been granted by the US Food and Drug Administration (FDA) a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells for both Stargardt’s Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world and Dry Age-Related Macular Degeneration (AMD) the most common form of macular degeneration in the world affecting an estimated 150 million people. ACT is using RPE cells developed from the patented (SCB) technique for this trial. The trial will take place at UCLA’s Jules Stein Eye Institute in California. Because of the biological nature of the human eye the trial will be able to provide a 100% irrefutable proof that the (hESC) derived RPE cells used attached to the Bruch’s membrane. Before and after state of the art imaging will take place.

Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world’s foremost experts in retinal cell physiology and vision restoration, commented, “The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run.”

FDA validation will occur for (hESC) medicine in less than 12 months. Will those that dictate law and morality to others lead? Will those suffering from disease all over the world finally have conclusive proof that (hESC) work? Life is filled with multifaceted choices and in a rare occurrence a quantum leap shows itself to the world. Human flight, computers and now regenerative medicine.

Disclosure: Stem Cell Media LLC nor its Companies was compensated by “any” entity for this article.www.investorstemcell.com is bringing investors and stakeholders together to participate in the world’s only online discussion forum dedicated to regenerative medicine.

Contact Details: icell@investorstemcell.com
www.investorstemcell.com

###

Biotech, Business, Financial, Healthcare, Pharmaceuticals, Science

NASDAQ:GERN & OTC:ACTC – A David & Goliath Comparison

Leave a comment

May 09, 2011 /RTPR/– Regenerative medicine is a highly complicated and vastly misunderstood science. Investor Stem Cell is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible advancements unfolding in the regenerative medicine sector. A quantum leap in health care is upon the world. Will you profit from this emerging sector & help bring cures to millions? Find out now what the street thinks at www.investorstemcell.com.

Side by side comparison of Advanced Cell Technology & Geron Corporation:

Geron Corporation (NASDAQ:GERN), Approved by the FDA to use human embryonic stem cell (hESC) treatments to treat spinal cord injuries. The research Goliath is a well-funded machine employing the top minds in the world working on everything from mid-stage oncology trials to promising (hESC) drugs for spinal cord injuries, heart disease & cancer.

Snap shot of Goliath: Geron Corpoartion-(NASDAQ:GERN)-
• Seven oncology Phase 2 trials currently underway, and has several big Pharma joint venture agreements in oncology animal and human trials
• Five hESC areas of investigation underway. GRNOPC1 is the lead candidate. Geron destroys the human embryo through its (hESC) R&D, of which the company uses the blastocyst embryo formation at day five after fertilization from IVF clinics
• Cash, restricted cash, cash equivalents and marketable securities: $221,274.000.00
• Total operating expenses in 2010: $114,730,000.00
• 175 employees; over 100 hold PhD or MD degrees
• Geron Corporation was founded in 1990 and is based in Menlo Park, California
• Trades on the NASDAQ providing liquidity & large institutional investors
• Corporate financial statements:http://www.geron.com/investors/reports/GeronAnnualReport2010.pdf

Advanced Cell Technology not too long ago was the predominant leader in the field of regenerative medicine. It fell from that distinction in part due to executive management hubris and ultimately the credit crisis in mid-2008. ACT was able to resurrect itself from near bankruptcy in June 2008 and now has the distinction of holding two out of the three FDA approved (hESC) trials. ACT is led by a competent executive management team and employs several of the most predominant regenerative researcher(s) in the world.

Snap shot of David: Advanced Cell Technology-(OTC:ACTC)-
• Retinal Pigment Epithelial Cell Program is their lead program-(HESC) trials for both SMD/AMD are expected to start in week(s) Jules Stein Eye Institute at the University of California, Los Angeles (UCLA ) will conduct the 2 (hESC) trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD)
• Filed a European Clinical Trial Application for Phase 1/2 study using (hESC) to treat macular degeneration
• Issued a broad patent for hESC-derived RPE cells in China
• Seeking funding & joint venture partner for Myoblast program for the treatment of cardiovascular disease Phase 2 approved by the FDA
• Joint ventured with Korean medical giant CHA to form “Stem Cell & Regenerative Medicine International” (SCRMI). This partnership expected to file an investigational new drug application (IND) with the FDA in Q-4 of this year. CHA biotech is waiting for final approval from the Korea Food and Drug Administration for (hESC) trial for AMD
• Issued patent on its “single-blastomere” technique. Patent Number 7,893,315 broadly covers ACT’s proprietary single-blastomere technology that provides a non-destructive alternative for deriving hESC lines. This “Embryo-Safe” one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo’s developmental potential
• 22 full-time employees, six hold PhD or MD degrees-Formed in 1994, HQ in Menlo Park, California with laboratory facilities in Marlborough, MA
• Total operating expenses in 2010: $22,044,701
• Cash, restricted cash, cash equivalents and marketable securities: $34,889,409
• Trades on the OTC:BB ACTC is a Sarbanes–Oxley Act SEC reporter
• Corporate financial statements:http://www.sec.gov/Archives/edgar/data/1140098/000101376211000631/form10k.htm

If you are looking for maximum possible ROI in the short term and can tolerate high risk, then maybe Advanced Cell Technology (OTC:ACTC) is for you? If ACT is validated by the FDA, the (RPE) MA-09 “embryo-safe” cell lines would open up an annual $25,000,000,000.00 market treating (AMD). Yes that is (b) with an (illion) annual market share! No FDA approved treatment exist for (AMD) in the world. This disease effects 30 million in the USA & EU alone. Cell lines have potential to treat 200 retinal eye diseases. ACT has been approved for U.S. Orphan Drug status protection for (SMD). This status by the FDA provides ACT seven years of market protection. ACT is expecting EU-Orphan Drug status for (SMD) and if awarded would receive 10-years of market protection. The recent patent protection for ACT’s RPE cells in China firmly establish potential world dominance of the (AMD) market. What is the down side? One glaring red flag is that ACT has two years of operating capital and enough cash to fund both the SMD/AMD Phase-1/2 trials in the U.S. If ACT’s AMD/SMD trials are not validated, ACT would most likely be forced to institute a massive reverse split due to the O/S nearing its A/S. ACT has placed all of its eggs in one pipeline basket, choosing the low hanging fruit model. ACT is counting on the exceptional Casey Eye Clinic animal results. Dr. Raymond Lund Ph.D., considered one of the world’s foremost experts in retinal cell physiology and vision restoration. Dr. Lund recently said the following: “The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run.”

Disclosure: www.investorstemcell.com is the world’s only online discussion forum dedicated bringing investors & stakeholders together in thoughtful discussion about stem cell & regenerative medicine. www.investorstemcell.com nor any of its Companies have been compensated by “any” party for this article. Before making an investment decision an investor should perform due diligences. Once completed find out what the street thinks at www.investorstemcell.com

Contact Details: www.investorstemcell.com
icell@investorstemcell.com

###

Biotech, Financial, Healthcare, Pharmaceuticals, Science

Investor Stem Cell Launches Online Discussion Community Dedicated To Stem Cell Investors

Leave a comment

APR 29, 2011 /RTPR/ — Investor Stem Cell (http://www.investorstemcell.com) is dedicated to bringing investors and stakeholders together in thoughtful discussion to educate and publicize the incredible medical advancements taking place in the regenerative medicine sector. Scientists are using stem cells both (hESC) and (iPSC) in hopes of easing the suffering of hundreds of millions of people world wide.

Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Regenerative medicine and Stem Cell research:

Utter those words at your next dinner party or casual gathering of friends and family. You will receive a concoction of half-truth’s and out right fallacy responses. Stem Cell research conjures images of futuristic Star–Trek like preservation chambers, human looking ears protruding oddly from the backs of mice, or worse yet an image of a late term fetus. Nothing could be farther from the truth when entering the reality of Regenerative medicine.

Never before has this area of research been more exciting and promising than right now. There is a medical revolution brewing, and like any revolution, there are those who want to suppress this uprising for continued personal and ideological gains. If we were to take all the major advances in the past 500 years of human medical history and multiply its effect by 10 fold it still would not compare to the paradigm shift in health care delivery that the world may witness in this decade using stem cells. Imagine that an $800,000 heart transplant is no longer needed and that instead the same money spent on one patient can now be stretched out to treat 20 patients who are needing a heart transplant. Is this what Regenerative medicine has in the offing? Only time will tell. Our healthcare system could very well be on the verge of a quantum leap moment thanks to regenerative medicine.

The Food and Drug Administration (FDA) authorized 3 trials using human embryonic stem cells (hESC) in late 2010. Validation of hESC research efforts and the culmination of billions spent on research are coming to fruition. FDA validation for the treatments of spinal cord injury and age related macular degeneration is expected in 2011. It may be the shot heard around the world event sometime in late Q-4 2011 for the Regenerative medicine sector.

Find out more at http://www.investorstemcell.com, where investing is much more than charts and numbers.

Investor Stem Cell offers dedicated forums to the following Stem Cell Companies.
Investor Stem Cell is free to all members and employs the state of the art discussion web based software to maximize the experience of its members and the user experience. Get involved now and start separating fact from fiction in Regeneration medicine.

Investor Stem Cell provides Forums for the below Stem Cell Companies.

Advanced Cell Technology (OTC:ACTC) Geron Corporation (NASDAQ:GERN)

Cord Blood America (Public, OTC:CBAI) BioTime (AMEX:BTX)

Aastrom Biosciences (NASDAQ:ASTM) Athersys Inc. (NASDAQ:ATHX)

International Stem Cell Corporation (OTC:ISCO) MultiCell (OTC:MCET)

StemCells, Inc. (NASDAQ:STEM) Thermogenesis (NASDAQ:KOOL)

Bioheart Inc. (OTC:BHRT) RTI Biologics (NASDAQ:RTIX)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) Bio-Matrix Scientific Group (PINK:BMSN)

Neuralstem (AMEX:NBS) Opexa Therapeutics (NASDAQ:OPXA)

Stem Cell Authority (PINK:SCLL) Brainstorm Cell Therapeutics (OTC:BCLI)

Stem Cell Therapeuitics (CVE:SSS) Cyro-Cell International (OTC:CCEL)

CellCyte Genetics(OTC:CCYG) Stem Cell Innovations (PINK:SCLL)

BioMimetic Therapeutics (NASDAQ:BMTI) Mesoblast (ASX:MSB)

Cytori Therapeutics (NASDAQ:CYTX) SANUWAVE Health, Inc. (OTC:SNWV)

Disclosure: By being a visitor and or member of Investor Stem Cell you agree to adhere to the Terms of Service at all times & pay strict attention to (TOS) Stem Cell Media LLC – http://www.investorstemcell.com is not paid by any 3rd party now or in the future to promote “any” companies for credibility and ethical reasons. Investors Stem Cell is not a financial advisory service. Consult your financial advisor at all times before making an investment. Our society is on the verge of a quantum leap moment in time thanks to regenerative medicine.

Contact Details: www.investorstemcell.com
email = icell@investorstemcell.com

###